New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease
Stockholm, September 10, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will present new preclinical data for the investigational anti-α-synuclein antibody ABBV-0805 at the International Congress of Parkinson’s disease and movement disorders® (MDS), held virtually September 17 to 22, 2021. The presentation, which has been selected as a Top Abstract, includes data showing ABBV-0805’s ability to selectively target soluble toxic α-synuclein aggregates.BioArctic will present one abstract at the congress, focusing on the preclinical findings that continue to support ABBV-0805 for